Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)

被引：0

作者：

Choueiri, T. K. ^{[1
]}

Kocsis, J. ^{[2
]}

Pachynski, R. K. ^{[3
]}

Poprach, A. ^{[4
]}

Deshazo, M. ^{[5
]}

Zakharia, Y. ^{[6
]}

Lara, P. N. ^{[7
]}

Pal, S. K. ^{[8
]}

Geczi, L. ^{[9
]}

Ho, T. H. ^{[10
]}

Mangel, L. ^{[11
]}

Redman, B. ^{[12
]}

Ryan, C. W. ^{[13
]}

Olencki, T. ^{[14
]}

Simpson, B. E. ^{[15
]}

Adams, B. ^{[15
]}

Robertson, L. ^{[15
]}

Darif, M. ^{[15
]}

Theuer, C. ^{[15
]}

Agarwal, N. ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[2] Debrecen Med Univ, Oncol, Debrecen, Hungary

[3] Siteman Canc Ctr, Oncol, St Louis, MO USA

[4] Masaryk Mem Canc Inst, Oncol, Brno, Czech Republic

[5] Univ Alabama Birmingham, Oncol, Birmingham, AL USA

[6] Univ Iowa, Hem Onc, Iowa City, IA USA

[7] Univ Calif Davis, Ctr Canc, Oncol, Sacramento, CA 95817 USA

[8] City Hope Natl Med Ctr, Oncol, Duarte, CA USA

[9] Natl Inst Oncol Hungary, Oncol, Budapest, Hungary

[10] Mayo Clin Arizona, Oncol, Phoenix, AZ USA

[11] Univ Pecs, Fac Med, PTE AOK, Oncol, Pecs, Hungary

[12] Univ Michigan, Oncol, Ann Arbor, MI 48109 USA

[13] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[14] Ohio State Univ, Oncol, Columbus, OH 43210 USA

[15] TRACON Pharmaceut Inc, Clin Res, San Diego, CA USA

[16] Huntsman Canc Inst, Oncol Internal Med, Salt Lake City, UT USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

912PD

引用

页码：362 / +

页数：2

共 50 条

[1] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Choueiri, T.
Agarwal, N.
Ho, T.
Pal, S. K.
Seon, B.
Jivani, M.
Adams, B.
Shazer, R.
Theuer, C.
ANNALS OF ONCOLOGY, 2016, 27
[2] TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus AXitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Choueiri, Toni K.
Agarwal, Neeraj
Ho, Thai H.
Pachynski, Russell
Pal, Sumanta
Ryan, Christopher W.
Vaena, Daniel
Lara, Primo
Lawler, William
Posadas, Edwin
Sonpavde, Guru P.
Wang, Peng
Gabrail, Nashat
Hammers, Hans-Joerg
Merchan, Jaime
Olencki, Thomas
Redman, Bruce
Sean, Ben K.
Adams, Bonne J.
Theuer, Charles P.
BJU INTERNATIONAL, 2015, 116 : 5 - 6
[3] Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR)
Choueiri, Toni K.
Zakharia, Yousef
Pal, Sumanta
Kocsis, Judit
Pachynski, Russell
Poprach, Alexandr
Nixon, Andrew B.
Liu, Yingmiao
Starr, Mark
Lyu, Jing
Owzar, Kouros
DeShazo, Mollie
Lara, Primo
Geczi, Lajos
Ho, Thai H.
Walsh, Meghara
Adams, Bonne
Robertson, Liz
Darif, Mohamed
Theuer, Charles
Agarwal, Neeraj
ONCOLOGIST, 2021, 26 (07): : 560 - +
[4] A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
Choueiri, T.
Michaelson, M. D.
Posadas, E.
Sonpavde, G.
McDermott, D.
Seon, B.
Jivani, M.
Shazer, R.
Adams, B.
Theuer, C.
ANNALS OF ONCOLOGY, 2016, 27
[5] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
Zibelman, Matthew R.
Geynisman, Daniel M.
Molina, Ana M.
Malizzia, Lois
Devarajan, Karthik
Luong, Diana
Sullivan, Elizabeth
Carducci, Michael Anthony
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] A phase 1b dose-escalation study of TRC105 (anti-Endoglin Antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
Choueiri, T. K.
Michaelson, M. D.
Posadas, E. M.
Sonpavde, G. P.
Mcdermott, D. F.
Sean, B. K.
Jivani, M. A.
Adams, B. J.
Theuer, C. P.
BJU INTERNATIONAL, 2015, 116 : 4 - 5
[7] A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
Choueiri, Toni K.
Posadas, Edwin M.
Sonpavde, Guru
Figlin, Robert A.
Walsh, Meghara K.
Wall, Kevin C.
Seon, Ben K.
Jivani, Manoi A.
Adams, Bonne J.
Theuer, Charles P.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.
Atkins, Michael B.
Bhatt, Rupal Satish
Voss, Martin Henner
Rini, Brian I.
Jonasch, Eric
Plimack, Elizabeth R.
Alter, Robert
Barger, Rachel
Wilson, Dawn
McClure, Ty
Kumar, Ravi
Attie, Kenneth M.
Sherman, Matthew L.
Pandya, Shuchi Sumant
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[9] An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
Choueiri, Toni K.
Michaelson, M. Dror
Posadas, Edwin M.
Sonpavde, Guru P.
McDermott, David F.
Nixon, Andrew B.
Liu, Yingmiao
Yuan, Zhenhua
Seon, Ben K.
Walsh, Meghara
Jivani, Manoj A.
Adams, Bonne J.
Theuer, Charles P.
ONCOLOGIST, 2019, 24 (02): : 202 - 210
[10] Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study
Rini, Brian I.
Gruenwald, Viktor
Fishman, Mayer N.
Melichar, Bohuslav
Ueda, Takeshi
Bair, A. H.
Chen, Ying
Bycott, Paul W.
Pavlov, Dmitri
Kim, Sinil
Jonasch, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)

← 1 2 3 4 5 →